The Nigerian pharmaceutical sector stands at a critical juncture as it seeks to pivot from a market dominated by imports toward a self-sustaining ecosystem of local production. At the heart of this transformation is the urgent need to manufacture Active Pharmaceutical Ingredients (APIs)—the essential raw materials that give drugs their therapeutic effect. This mandate was the primary focus of the 2026 Nigeria Pharma Manufacturers’ Expo in Lagos, where industry stakeholders, policymakers, and international experts gathered to chart a course for the future of domestic drug manufacturing.

Paresh Jurmarwala, founder and CEO of GPE Expo Limited, emphasized that the transition to local API production is not merely an industrial goal but a prerequisite for national health security. Speaking on the sidelines of the expo, Jurmarwala argued that Nigeria’s current reliance on imported finished products leaves the economy vulnerable to global supply chain shocks and the volatility of foreign exchange markets.

The Strategic Imperative of Backward Integration

The concept of "backward integration" serves as the foundational strategy for Nigeria’s industrial roadmap. According to Jurmarwala, who has facilitated pharmaceutical trade and technology exchange across 11 countries, the path forward mirrors the development trajectories of global pharmaceutical powerhouses like India and Bangladesh.

In the early stages of India’s pharmaceutical ascent, the nation focused heavily on producing finished dosage forms—tablets, capsules, and syrups—while relying on China for the bulk supply of APIs. It was only through a deliberate, multi-decade policy shift that India transitioned into a global hub for API manufacturing. A similar blueprint was utilized in Bangladesh, where the government incentivized the creation of dedicated API parks. Today, these parks host dozens of specialized manufacturers, effectively lowering the cost of production and insulating the domestic market from international price fluctuations.

For Nigeria, the goal is to replicate this phased evolution: starting with local assembly and formulation, moving into domestic API synthesis, and eventually expanding into high-value sectors such as clinical research and the production of biosimilars.

Market Size and Commercial Viability

A common critique of local manufacturing in Africa has historically been the lack of economies of scale. However, industry analysts at the 2026 Expo noted that Nigeria’s demographic profile—a population exceeding 200 million—offers a unique advantage.

Jurmarwala illustrated the concept of "market threshold" using the example of paracetamol. A product with low demand might not justify the high capital expenditure required for an API facility. However, as the population’s purchasing power grows and the healthcare system expands, the consumption of essential medicines hits a critical mass—perhaps 50 tonnes of a specific ingredient—that makes local production commercially viable.

"When the requirement reaches a specific threshold, local manufacturing becomes the natural, profitable evolution," Jurmarwala explained. This shift is expected to trigger a cascade effect, creating demand for local chemical suppliers, packaging manufacturers, and specialized logistics, thereby fostering a robust industrial value chain.

The Role of Technology Transfer and Global Standards

The 2026 Nigeria Pharma Manufacturers’ Expo serves as more than just a trade show; it acts as a knowledge-transfer hub. Over his 16 years of engagement with the Nigerian market, Jurmarwala has witnessed a significant shift in the ambitions of local manufacturers. The expo provides a platform for Nigerian firms to access information on World Health Organization (WHO) Good Manufacturing Practice (GMP) standards and European Union (EU) GMP compliance.

These international certifications are the "gold standard" for the pharmaceutical industry. Without them, Nigerian-made drugs struggle to gain access to international markets, effectively locking them within the domestic sphere. By aligning with these global benchmarks, Nigerian companies can pivot from being domestic suppliers to regional exporters, tapping into the broader African Continental Free Trade Area (AfCFTA).

Government Procurement as a Catalyst

The discussion at the Expo also touched upon the critical role of the federal government in stimulating the sector. Manufacturers have long cited unstable electricity and the high cost of capital as major deterrents to growth. However, Jurmarwala argued that the most powerful tool in the government’s arsenal is its own purchasing power.

"When the government commits to procuring quality, locally manufactured products, it provides the guaranteed demand that investors need to justify the high cost of WHO-compliant facilities," he stated. A policy favoring locally produced medicines—provided they meet stringent quality benchmarks—would create a sustainable feedback loop: increased demand leads to higher investment, which leads to better infrastructure, ultimately resulting in more affordable and accessible medication for the public.

Challenges and the Path Toward Industrial Maturity

Despite the optimism, the industry faces systemic hurdles. Reliable energy remains the most significant operational challenge for pharmaceutical plants, which require constant, stable power to maintain climate-controlled environments and run sophisticated machinery. While individual manufacturers have adopted captive power solutions—such as gas-powered plants and solar arrays—these add to the total cost of production.

Furthermore, the "brain drain" of skilled pharmaceutical professionals continues to be a concern. To combat this, industry leaders are advocating for increased investment in specialized human capital. The proposal is to facilitate international training programs where Nigerian pharmacists and engineers can study advanced manufacturing processes abroad and return to implement these technologies locally.

"We are seeing a growing interest in technology acquisition," Jurmarwala noted. "The industry is moving past the stage of simply wanting to trade; there is a genuine desire to manufacture, innovate, and export."

Broader Implications for the African Continent

The transformation of Nigeria’s pharmaceutical landscape has implications that extend far beyond its borders. As the largest economy in West Africa, Nigeria’s success in establishing a localized API and manufacturing ecosystem could provide a model for the rest of the continent.

The integration of the pharmaceutical sector into the wider healthcare economy—encompassing hospital partnerships, biotechnology, and health-tech—is becoming a central pillar of Africa’s economic development strategy. The 2026 Expo highlighted that the continent’s healthcare needs are not just a social challenge but an immense economic opportunity.

Conclusion: A Vision for 2030 and Beyond

As the curtains closed on the 2026 Nigeria Pharma Manufacturers’ Expo, the consensus was clear: the era of total dependence on imported finished pharmaceuticals is nearing its end. The transition toward backward integration will require sustained collaboration between the private sector, regulatory bodies like the National Agency for Food and Drug Administration and Control (NAFDAC), and federal policymakers.

If Nigeria can successfully leverage its large domestic market to attract investment in API manufacturing and adhere to international quality standards, the nation is poised to become a regional pharmaceutical hub. By fostering a culture of innovation, investing in human capital, and prioritizing local consumption, Nigeria is taking the necessary steps to secure its health sovereignty in an increasingly uncertain global landscape. The journey toward a self-reliant pharmaceutical industry is arduous, but as evidenced by the growing number of manufacturers exploring export markets, the momentum is clearly building.